ProQR Therapeutics (PRQR) Net Margin (2012 - 2026)
ProQR Therapeutics (PRQR) posted quarterly Net Margin of 658.29% for Q1 2026, down 43525.0% year-on-year from N/an in Q1 2025, and down 293.43% on a QoQ basis from 167.32% in Q4 2025.
ProQR Therapeutics (PRQR) Net Margin (2012 - 2026) Analysis & Trends
ProQR Therapeutics (PRQR) has reported Net Margin for 15 consecutive years, with 658.29% the latest figure, recorded in Q1 2026.
- Quarterly Net Margin fell 43525.0% year-over-year to 658.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 336.19% (down 17566.0% YoY) and the FY2025 annual result came in at 265.21%, down 11835.0% from the prior year.
- Net Margin retreated to 658.29% in Q1 2026 per PRQR's latest filing, from 167.32% in the prior quarter.
- Over the last five years, Net Margin for PRQR reached as high as 42.7% in Q2 2024 and fell as low as 2864.62% in Q3 2022.
- A 5-year average of 735.46% and a median of 382.69% in 2025 frame the typical range for Net Margin.
- The largest YoY upside for Net Margin was 577704 bps in 2022 against a maximum downside of 114442 bps in 2022.
- Year by year, Net Margin stood at 1846.81% in 2022, then jumped by 92 bps to 150.3% in 2023, then slumped by 42 bps to 213.7% in 2024, then rose by 22 bps to 167.32% in 2025, then sank by 293 bps to 658.29% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 658.29%, 167.32%, and 382.69% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | ProQR Therapeutics | 219.53 Mn | 175.72 Mn | - | -658.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -658.29% |
| Dec 31, 2025 | -167.32% |
| Sep 30, 2025 | -382.69% |
| Jun 30, 2025 | -336.94% |
| Mar 31, 2025 | -223.04% |
| Dec 31, 2024 | -213.70% |
| Sep 30, 2024 | -220.79% |
| Jun 30, 2024 | -42.70% |
| Mar 31, 2024 | -172.09% |
| Dec 31, 2023 | -150.30% |
| Sep 30, 2023 | -441.24% |
| Jun 30, 2023 | -663.32% |
| Mar 31, 2023 | -1,397.25% |
| Dec 31, 2022 | -1,846.81% |
| Sep 30, 2022 | -2,864.62% |
| Jun 30, 2022 | -1,473.12% |
| Mar 31, 2022 | -1,248.58% |
| Dec 31, 2021 | -7,623.85% |
| Sep 30, 2021 | -1,725.57% |
| Jun 30, 2021 | -6,537.86% |